Corporate Banner
Satellite Banner
Cell Culture
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Affymetrix and ScreenCell Announce Worldwide Distribution Agreement

Published: Friday, May 18, 2012
Last Updated: Friday, May 18, 2012
Bookmark and Share
Affymetrix releases first circulating tumour cell platform technology for 4-color RNA-ISH.

Combination of ScreenCell's isolation devices and Affymetrix' QuantiGene(R) ViewRNA ISH technology enables easy, accessible, sensitive, multiplex, low-cost system to enumerate and characterize CTCs and other rare cells.

Affymetrix, Inc. and ScreenCell announced the signing of a worldwide distribution agreement for ScreenCell's isolation devices and dilution buffers, designed for the collection of Circulating Tumor Cells (CTCs) in peripheral blood.

The agreement makes Affymetrix the exclusive distributor of ScreenCell(R) products* used in combination with in situ hybridization (ISH) assays, microarray assays, and other non-PCR based nucleic acid assays including Affymetrix' industry-leading QuantiGene(R) ViewRNA Assays,* QuantiGene(R) Plex Assays,* and GeneChip(R) Microarray Assays.* The QuantiGene(R) ViewRNA CTC platform, consist of ScreenCell's products and Affymetrix' QuantiGene ViewRNA Assays, is now available from Affymetrix.

"This agreement is a powerful combination of two innovative technologies, one designed to isolate rare cells of potentially significant prognostic and predictive value in cancer, and another, our QuantiGene ViewRNA ISH Cell Assays, designed to detect single RNA transcripts in single CTCs and rare cells with high specificity," stated George Bers, Vice President & General Manager, Expression Business Unit -- Panomics for Affymetrix. "Today we are launching our CTC platform, which combines our highly sensitive and specific QuantiGene ViewRNA Assay with ScreenCell's isolation devices. We believe this platform may potentially have a dramatic impact on disease detection, enabling researchers in translational sciences to further examine the impact on treatment, management and outcome in cancer. We are proud to be ScreenCell's global partner and look forward to releasing additional assays and research applications."

ScreenCell offers innovative, single-use devices to isolate by size and characterize a wide variety of tumor cells, both live and fixed, including mesenchymal cells, cancer stem cells, microembolii and cancer cells of non-epithelial origin. These cells, which are considered to be important in metastasis, are often not captured or cannot be sensitively detected through existing technologies that only target cells expressing EpCam, a transmembrane glycoprotein on epithelial cells. With the ScreenCell devices, collected cells are also well preserved morphologically and can be isolated and grown in culture for drug screening or further genomics analysis.

"Our goal in designing ScreenCell(R) technologies was to create a universal system, not limited to detection of cells of non-epithelial origin and free of any bias potentially linked to the use of antibodies for cell capture," stated David Znaty, Chief Executive Officer of ScreenCell. "Our goal is to provide a technology to support further research for use in personalized medicine by creating a broadly accessible, non-invasive evaluation of specific, potential therapeutic targets. We are excited to work with Affymetrix not just for their commercial strength, but because we believe strongly in our combined technologies."


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,900+ scientific posters on ePosters
  • More than 5,300+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.


Scientific News
Stem Cells in Drug Discovery
Potential Source of Unlimited Human Test Cells, but Roadblocks Remain.
Making Personalized Medicine a Reality
Groundbreaking technique developed at McMaster University is helping to pave the way for advances in personalized medicine.
Regenerating Diseased Hearts
Researchers from the University of Otago have probed the potential of adult stem cell types to repair diseased hearts.
Color-Coded Stem Cells
Researchers develop colour-coding tool for tracking live blood stem cells over time.
Using Cancer Cells' Mass to Predict Treatment Response
A device has been developed that can detect changes in cell mass at a minute scale.
Human Intestines and Functioning Nerves Engineered
The new technology enables the study of human health and advances the goal of regenerative medicine.
Chemical Snapshots Could Lead to Better Engineered Cartilage
Taking "chemical photographs" of the cartilage between joints and comparing it to engineered versions could lead to better implants, say researchers.
Peer Review is in Crisis, But Should be Fixed, Not Abolished
After the time to get the science done, peer review has become the slowest step in the process of sharing studies, and some scientists have had enough.
New Model of Lung Regeneration
Scientists have developed a tissue-engineered model of lung and trachea which contains the different cell types found in the repiratory system.
Cause of Inflammation in Diabetes Identified
Suprise discovery has identified a possible trigger of chronic inflammation in diabetes.
Skyscraper Banner

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,900+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
5,300+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!